International Journal of Medical and Pharmaceutical Research
2024, Volume-5, Issue-1 doi: 10.5281/zenodo.10807262
Original Article
Two Weeks Dose Range Finding Study of KSM-66 Ashwagandha Root Extract by Oral Route in Wistar Rats – A Toxicity Study
 ,
 ,
Published
Feb. 29, 2024
Abstract

Ashwagandha (Withania Somnifera) is widely used as an adaptogenic medicinal herbin Ayurveda, the Indian system of Medicine. This study assessedpotential toxic effects associated with repeated oral administration of Ashwagandha root extract (ARE) for two weeks in Wistar rats. Twenty male and female Wistar rats were assigned to four groups viz., control, ARE (500/1000/2000 mg/kg body weight per day). Animals were observed for mortality/morbidity, clinical signs of toxicity (daily cage side observation), clinical examination (gait, mobility, arousal level, respiration, clonic/tonic movement, stereotype, bizarre behaviour, defecation, urine pools, vocalization, and rearing) prior to dosing and before necropsy day, body weight (weekly), and feed consumption. After 14 days, the animals were euthanized (CO2) and subjected to detailed gross necropsy (examination of external orifices, cranial, thoracic, and abdominal cavities, and their contents). Organs (liver, kidney, heart, spleen, brain, adrenal, thymus, ovaries, uterus with cervix, testes, and epididymis) were removed and weighed. No clinical signs of toxicity were observed with Ashwagandhatreated groups, and it had nosignificant (p>0.05) effect on body weight and feed consumption by animals compared to control. No differences (p>0.05) were observed between ARE treated animals and control with respect to the absolute and relative organ weightand gross pathological findings. Ashwagandha root extract was found to be well tolerated in doses up to 2000 mg/kg body weight administered orally for 14 days in Wistar rats.

Recommended Articles
Loading Image...
Volume-5, Issue-1
Citations
1988 Views
501 Downloads
Share this article
License
Copyright (c) International Journal of Medical and Pharmaceutical Research
pdf Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 International License.
All papers should be submitted electronically. All submitted manuscripts must be original work that is not under submission at another journal or under consideration for publication in another form, such as a monograph or chapter of a book. Authors of submitted papers are obligated not to submit their paper for publication elsewhere until an editorial decision is rendered on their submission. Further, authors of accepted papers are prohibited from publishing the results in other publications that appear before the paper is published in the Journal unless they receive approval for doing so from the Editor-In-Chief.
IJMPR open access articles are licensed under a Creative Commons Attribution-ShareAlike 4.0 International License. This license lets the audience to give appropriate credit, provide a link to the license, and indicate if changes were made and if they remix, transform, or build upon the material, they must distribute contributions under the same license as the original.
Logo
International Journal of Medical and Pharmaceutical Research
About Us
The International Journal of Medical and Pharmaceutical Research (IJMPR) is an EMBASE (Elsevier)–indexed, open-access journal for high-quality medical, pharmaceutical, and clinical research.
Follow Us
© Copyright IJMPR | All Rights Reserved